Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

UCB : Transparency notification of Vanguard Health Care Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
04/11/2012 | 08:41pm CEST

Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), April 11, 2012 - 7.30 p.m. (CET) - regulated information - Vanguard Health Care Fund (having its registered offices c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 - USA) acquired 5,821,811 UCB shares with voting rights (on a total number of 183,365,052) on March 30, 2012, representing 3.17% of UCB's share capital, which means that Vanguard Health Care Fund crossed the threshold of notification of 3%.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608

For further information

Antje Witte, Investor Relations, UCB

T +32.2.559.9414, [email protected]

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on UCB
03/23UCB : Convening notice to attend the general meeting of shareholders to be held ..
03/15UCB : Data on Cardiology Detailed by Researchers at UCB S.A. (miR-21-5p as a pot..
03/08UCB : Patent Issued for Systems and Methods for Administering Medication (USPTO ..
02/21Arix, Fosun in China-focused deal
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Academy &hellip..
02/08UCB : Findings on Therapeutics Research Reported by Investigators at UCB S.A. (U..
02/08UCB : New Findings on Biomarkers Described by Investigators at UCB S.A. (Dampeni..
01/31UCB : Transparency Notification
01/29UCB : Transparency Notification
01/19UCB S.A. REPORTS FINDINGS IN PARKINS : A randomized,...
More news
News from SeekingAlpha
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/19Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket 
01/08EMA accepts UCB's marketing application for osteoporosis med romosozumab 
Financials (€)
Sales 2018 4 546 M
EBIT 2018 1 117 M
Net income 2018 774 M
Finance 2018 100 M
Yield 2018 1,90%
P/E ratio 2018 15,83
P/E ratio 2019 14,14
EV / Sales 2018 2,77x
EV / Sales 2019 2,56x
Capitalization 12 693 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 68,8 €
Spread / Average Target 5,5%
EPS Revisions
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.39%15 679
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-8.64%207 583
PFIZER-1.71%205 314
ROCHE HOLDING LTD.-12.37%196 669
MERCK AND COMPANY-5.08%144 004